A pharmaceutical company fueling most of its rapid growth through acquisitions, Valeant (NYSE:VRX) responded to a short-seller’s accusations this week by announcing a change of business model at its 2015 Investor Day.
021 712 5410
mcarthurfps@global.co.za
